Related Experiment Video
Updated: Jun 14, 2026
07:39
Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
Published on: January 7, 2019
Enhancing existing approaches to peripheral T-cell lymphoma
1Yale Cancer Center, New Haven, CT, USA. francine.foss@yale.edu
Seminars in Hematology
|April 3, 2010
Summary
Peripheral T-cell lymphoma (PTCL) lacks standard treatments, leading to poor outcomes. New first-line therapies and individualized treatment plans are crucial for improving patient survival and transplant success.
Area of Science:
- Oncology
- Hematology
Background:
- Peripheral T-cell lymphoma (PTCL) presents a significant therapeutic challenge due to a lack of established treatment protocols.
- Conventional therapies, often adapted from B-cell lymphomas, yield suboptimal outcomes in PTCL patients.
Purpose of the Study:
- To highlight the limitations of current PTCL treatment strategies.
- To explore novel therapeutic approaches for improving patient outcomes in PTCL.
Main Methods:
- Review of National Comprehensive Cancer Network (NCCN) guidelines for PTCL.
- Analysis of treatment strategies, including novel agents and individualized approaches.
Main Results:
- Current PTCL treatments show poor efficacy.
- Novel agents like denileukin diftitox and tailored treatment regimens show promise.
Conclusions:
- Effective first-line therapy is essential for enabling patients to reach transplant.
- Individualizing PTCL treatment based on histopathologic subtype is critical for optimizing patient response and survival.
